I expect the announcement to be about the next phase of...

I expect the announcement to be about the next phase of incorporating OBJ technology into 3M products and its benefit to OBJ.

Based on the study last year, the performance has already been proven and published, and the remaining risk is to do with incorporation with 3M products and manufacturing.

Thus the probability of incorporation = high. Consequence to OBJ = high. This is not a risk, this is an opportunity.

Ref:
"The Materials Transfer Agreement sets the parameters for an initial in vitro testing program to evaluate the performance of the eM‐patch technology in conjunction with 3M drug delivery platforms and proprietary formulations. The evaluation program is expected to be completed by 1st February 2010."